pembrolizumab,toripalimab,nivolumab,ipilimumab,Atezolizumab,durvalumab
merck,Roche,BMS,Coherus,Junshi Biosciences,Astrazeneca
['nsclc', 'sclc']
amazing discussion by a wonderful mentor about neoadjuvant &amp; adjuvant immune-based strategies for patients with early-stage #nsclc 
Research Fellow @DanaFarber | @Harvardmed, Boston. Medical Oncology Fellow @Unibo, IRCCS Sant’Orsola-Malpighi